SPOTLIGHT: Shire gets Vyvanse nod for adult use


Shire got its longed-for blessing from the FDA to sell Vyvanse, an ADHD treatment, for use in adults. Some one-third of Vyvanse scrips already go to grownups, off-label, but the FDA OK will let Shire promote the med--and promote it, it will. Release | Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.